Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAXIRI: XELIRI + Bevacizumab in Metastatic Colorectal Cancer
NCT00875771Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Apr 2009
- Primary completion
- May 2012
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression Free Survival. Started Apr 2009; status: completed.
02
Drugs
capecitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00875771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00875771.